Clinical Trial Update: Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment [EARLY_Phase 1]

View source ↗

Summary

Early-phase pharmacokinetics study of a Centella Asiatica product in mild cognitive impairment was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Centella Asiatica product (CAP) (Centella asiatica extract)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Cognitive Impairment, Elderly | EARLY_Phase 1 | Status: TERMINATED | Results posted: 2022-05-04